Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|April 18, 2026
Oncology Experts Preview Abstracts to Watch at the 2026 AACR Annual Meeting
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.
Advertisement
Advertisement
As the
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Advertisement
Advertisement